论文部分内容阅读
目的探讨血必净联合头孢他啶治疗肺部感染合并脑梗死的临床疗效。方法选取60例肺部感染合并脑梗死患者为研究对象,随机分为观察组和对照组,每组30例。对照组给予头孢他啶治疗,观察组给予血必净联合头孢他啶治疗,比较两组患者临床疗效及治疗前后血清白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)表达水平。结果治疗后,两组患者血清IL-6和TNF-ɑ表达水平均明显降低,与治疗前比较差异有统计学意义(P<0.05);与对照组比较,观察组血清IL-6和TNF-ɑ表达水平下降更为明显,组间比较差异有统计学意义(P<0.05)。观察组和对照组治疗有效率分别为93.3%(28/30)和70.0%(21/30),两组比较差异有统计学意义(P<0.05)。结论血必净联合头孢他啶治疗肺部感染合并脑梗死患者,可有效降低血清IL-6及TNF-α等炎症因子表达,提高临床疗效,从而有效改善患者临床预后。
Objective To investigate the clinical efficacy of Xuebijing combined with ceftazidime in the treatment of pulmonary infection complicated with cerebral infarction. Methods Sixty patients with pulmonary infection and cerebral infarction were selected as study subjects and randomly divided into observation group and control group, 30 cases in each group. The control group was treated with ceftazidime. The observation group was given Xuebijing combined with ceftazidime. The clinical curative effect and the levels of serum IL-6 and TNF-α before and after treatment were compared between two groups. Results After treatment, the serum levels of IL-6 and TNF-ɑ in both groups were significantly lower than those before treatment (P <0.05). Compared with the control group, the levels of IL-6 and TNF- ɑ expression decreased more significantly, the difference between the two groups was statistically significant (P <0.05). The effective rates of the observation group and the control group were 93.3% (28/30) and 70.0% (21/30), respectively. The difference between the two groups was statistically significant (P <0.05). Conclusion Xuebijing combined with ceftazidime in patients with pulmonary infection complicated with cerebral infarction can effectively reduce the expression of serum IL-6 and TNF-α and other inflammatory factors and improve clinical curative effect, so as to effectively improve the clinical prognosis of patients.